1. Scheithauer W, Von Hoff DD, Clark GM, Shillis JL, Elslager EF: In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol 22:921–926, 1986
2. Waud WR, Plowman J, Paull KD, Narayanan VL, Bailey DM, Harrison SD, Dykes DJ, Laster WR, Griswold DP: Preclinical antitumor activity of Hepsulfam (NSC-329680). (Abstract) Proc Amer Assoc Cancer Res 29:1323, 1988
3. Baker DC, Hand ES, Plowman J, Rampal JB, Safavy A, Haugwitz RD, Narayanan VL: Synthesis, chemical stability and preclinical anti-tumor activity of pyrazine diazohydroxide, sodium salt (NSC-361456). Anti-Cancer Drug Design 2:297–309, 1987
4. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW: Inhibition of type II topoisomerase by Fostriecin. Biochem Pharmacol 37:4063–4068, 1988
5. Jackson RC, Fry DW, Boritzki TJ, Roberts BJ, Hook KE, Leopold WR: The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regulation 23:193–215, 1985